Investors of PROCEPT BioRobotics Face Class Action Lawsuit by Hagens Berman

Class Action Lawsuit Against PROCEPT BioRobotics

On August 20, 2026, Hagens Berman Sobol Shapiro LLP announced a securities class action lawsuit concerning PROCEPT BioRobotics Corporation (NASDAQ: PRCT). This legal action stems from alarming revelations about the company’s sales practices and inventory management, prompting the firm to represent investors who acquired PROCEPT's common stock between February 28, 2024, and February 25, 2026.

Background of the Case

The lawsuit arises from recent reports indicating that PROCEPT has dramatically underperformed in unit sales of its single-use handpieces, which are essential components of its proprietary Aquablation therapy aimed at treating enlarged prostates. The suit alleges that the company misled investors through inadequate disclosures regarding sales practices, particularly the use of bulk discounts that incentivized customers to over-order, leading to artificially inflated sales figures.

According to the complaint, these practices negatively impacted future sales, creating a challenging environment for PROCEPT and its investors. It claims that the management's continued promotion of handpiece sales growth misrepresented the company's actual financial health.

Key Allegations and Developments

Several significant events have contributed to the unfolding of this case. The firm points out that investors began receiving critical information in stages. On August 6, 2025, PROCEPT’s announcement of their Q2 2025 financial results revealed a substantial decline in handpiece sales, which fell far below market expectations. Subsequently, on November 4, 2025, the company reported further declines in Q3 results and significantly revised its annual sales guidance, citing management's failure to control customer inventories.

The most revealing moment came on February 25, 2026, when PROCEPT reported its Q4 results. For the first time, they unveiled the actual number of procedures utilizing their handpieces. Disturbingly, the data showed a consistent rise in inventory levels, with over 10,000 excess units held by customers, while handpiece sales had plummeted by 30% quarter-over-quarter. However, management attempted to mask these trends by eliminating undisclosed bulk ordering discounts that had distorted sales figures.

Due to these revelations, the stock price of PROCEPT saw a significant drop, declining over 48% since the August 2025 financial report. Hagens Berman's investigation is focused on whether PROCEPT intentionally manipulated sales reporting to align with earnings expectations or if they failed to provide sufficient transparency in their financial communications.

The Role of Investors and Whistleblowers

Investors affected by these developments are encouraged to reach out and share their experiences of financial loss. Hagens Berman invites individuals with any relevant information that may assist the investigation to come forward. Moreover, the firm has highlighted the SEC's Whistleblower Program, which offers rewards for individuals who provide original information concerning violations of securities laws.

Hagens Berman Sobol Shapiro LLP has a strong reputation as a plaintiffs' rights firm, having recovered over $2.9 billion for clients harmed by corporate negligence. They are committed to achieving justice on behalf of investors who have suffered due to the alleged misconduct at PROCEPT BioRobotics.

Conclusion

As this case progresses, affected shareholders should consider their options carefully, especially with the Lead Plaintiff deadline set for September 22, 2026. The outcome of this lawsuit could significantly impact PROCEPT BioRobotics as well as its investors moving forward. For any further inquiries or to explore options, investors should visit the Hagens Berman website or contact their attorneys directly. This lawsuit underscores the importance of transparency and integrity in corporate practices, especially within the high-stakes arena of biotechnology and pharmaceuticals.